Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

ABSTRACT:

Introduction

The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic effects and to examine the correlations among outcome measures.

Methods

The study was a multicenter, randomized, placebo-controlled trial of two dose regimens of semagacestat and a placebo administered for 18 months to individuals with mild to moderate AD. Changes in measures of central and peripheral drug activity were compared between the three treatment groups using one-way analysis of variance. The relationship between changes in each of the outcome measures and measures of dr

SUBMITTER: Doody RS 

PROVIDER: S-EPMC4461930 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature